FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2554332656> ?p ?o ?g. }

• W2554332656 abstract "Objectives To know the usefulness of follow-up call legalized at the beginning of biologic therapy and patient contact with consultation of nursing after the start of treatment. Methods Observational study cross.Patients: We collected 120 patients who began treatment with biologic therapy, intravenous or subcutaneous from December 2013 to November 2015. Protocol: Protocol is education for self-management of subcutaneous biological therapy at the beginning of the treatment. This Protocol includes a follow-up call from the consultation of nursing that matches the first administration of the treatment at home or within 3–5 days after the first infusion. This call is made in the case of the biological subcutaneous as per guideline: etanercept (7 days), adalimumab (14 days), golimumab (28 days), tocilizumab (7days), certolizumab (14 days), abatacept (7days) either guideline prescribed in case of dose reduction. Offers the possibility of contact (telephone and e-mail) with the consultation of nurses in case of doubt or incidence during treatment and is analytical control to the month of the beginning of nurse telephone consultation. Statistical analysis: a descriptive analysis of the main variables. Results 120 patients with RA initiated treatments were: etanercept 33,3% (n40), adalimumab 8,3% (10), tocilizumab sc 20% (24), abatacept sc 12,5% (15), golimumab 13,3% (16), rituximab 6,7% (8), certolizumab pegol 3,3% (4), biosimilar 2,5% (3). In terms of the associated FAME: none 38,3% (46), methotrexate 49,2% (59), Leflunomide 8.3% (10), sulfasalazine 1,7% (2), hydroxychloroquine 2,5% (3).They were detected in the Protocol call patients with incidences 14,16% (17): local reaction3.3% (4), pruritus 5.8% (7), upset general 0.8% (1), diarrhea 0.8% (1), constipation 0.8% (1), headache 1.7% (2). The patients called the nursing consultation to communicate incidences 10.83% (13): anemia 0.8% (1), hypertransaminasemia 1,7% (2), implant dental 0.8% (1), bruising 0,8% (1), inefficiency 6.7% (8). Also communicated to the consultation of nursing infections during 16.6% (20): urinary tract infection 5,8% (7), upper respiratory tract infection 1,7% (2), upper respiratory tract infection+herpes simplex 0,8% (1), lower respiratory tract infection 3,3% (4), surgical wound infection 0.8% (1), dental infection 0,8% (1), herpes simplex 0,8% (1), gastroenteritis 0,8% (1), not frightening infection 1,7% (2).Patients who started biologic therapy in the period studied only 8.3% (10) changed treatment.The emergence of new comorbidities were detected during treatment with biologic therapy 4,16% (5): hypertension 0,8% (1), hypertension + diabetes mellitus II 1,7% (2), nonspecific Interstitial pneumonia 0,8% (1), psoriasis 0,8% (1). Conclusions The follow-up call is a useful tool for the control of security of the new beginnings of biological agents. It could foster adherence to treatment monitoring at home and offering the possibility to communicate with the nursing. Disclosure of Interest None declared" @default.
• W2554332656 created "2016-11-30" @default.
• W2554332656 creator A5015009380 @default.
• W2554332656 creator A5025822241 @default.
• W2554332656 creator A5029785696 @default.
• W2554332656 creator A5030223048 @default.
• W2554332656 creator A5034211653 @default.
• W2554332656 creator A5044321542 @default.
• W2554332656 creator A5054792245 @default.
• W2554332656 creator A5056965752 @default.
• W2554332656 creator A5059356952 @default.
• W2554332656 creator A5069117824 @default.
• W2554332656 creator A5076093930 @default.
• W2554332656 creator A5076985983 @default.
• W2554332656 creator A5082442829 @default.
• W2554332656 creator A5083166719 @default.
• W2554332656 date "2016-06-01" @default.
• W2554332656 modified "2023-09-27" @default.
• W2554332656 title "AB1078-HPR Telephone Follow-Up, Standardized To The Initiation of Biologic Therapy of Patients with Rheumatoid Arthritis (RA) in A Specific Unit of Biologic Therapy. Pilot Study" @default.
• W2554332656 doi "https://doi.org/10.1136/annrheumdis-2016-eular.1432" @default.
• W2554332656 hasPublicationYear "2016" @default.
• W2554332656 type Work @default.
• W2554332656 sameAs 2554332656 @default.
• W2554332656 citedByCount "1" @default.
• W2554332656 countsByYear W25543326562018 @default.
• W2554332656 crossrefType "journal-article" @default.
• W2554332656 hasAuthorship W2554332656A5015009380 @default.
• W2554332656 hasAuthorship W2554332656A5025822241 @default.
• W2554332656 hasAuthorship W2554332656A5029785696 @default.
• W2554332656 hasAuthorship W2554332656A5030223048 @default.
• W2554332656 hasAuthorship W2554332656A5034211653 @default.
• W2554332656 hasAuthorship W2554332656A5044321542 @default.
• W2554332656 hasAuthorship W2554332656A5054792245 @default.
• W2554332656 hasAuthorship W2554332656A5056965752 @default.
• W2554332656 hasAuthorship W2554332656A5059356952 @default.
• W2554332656 hasAuthorship W2554332656A5069117824 @default.
• W2554332656 hasAuthorship W2554332656A5076093930 @default.
• W2554332656 hasAuthorship W2554332656A5076985983 @default.
• W2554332656 hasAuthorship W2554332656A5082442829 @default.
• W2554332656 hasAuthorship W2554332656A5083166719 @default.
• W2554332656 hasConcept C126322002 @default.
• W2554332656 hasConcept C142724271 @default.
• W2554332656 hasConcept C1862650 @default.
• W2554332656 hasConcept C2776215756 @default.
• W2554332656 hasConcept C2777138892 @default.
• W2554332656 hasConcept C2777178219 @default.
• W2554332656 hasConcept C2777226972 @default.
• W2554332656 hasConcept C2777575956 @default.
• W2554332656 hasConcept C2779134260 @default.
• W2554332656 hasConcept C2779338263 @default.
• W2554332656 hasConcept C2779605438 @default.
• W2554332656 hasConcept C2780132546 @default.
• W2554332656 hasConcept C2780182762 @default.
• W2554332656 hasConcept C2780653079 @default.
• W2554332656 hasConcept C2781290027 @default.
• W2554332656 hasConcept C71924100 @default.
• W2554332656 hasConceptScore W2554332656C126322002 @default.
• W2554332656 hasConceptScore W2554332656C142724271 @default.
• W2554332656 hasConceptScore W2554332656C1862650 @default.
• W2554332656 hasConceptScore W2554332656C2776215756 @default.
• W2554332656 hasConceptScore W2554332656C2777138892 @default.
• W2554332656 hasConceptScore W2554332656C2777178219 @default.
• W2554332656 hasConceptScore W2554332656C2777226972 @default.
• W2554332656 hasConceptScore W2554332656C2777575956 @default.
• W2554332656 hasConceptScore W2554332656C2779134260 @default.
• W2554332656 hasConceptScore W2554332656C2779338263 @default.
• W2554332656 hasConceptScore W2554332656C2779605438 @default.
• W2554332656 hasConceptScore W2554332656C2780132546 @default.
• W2554332656 hasConceptScore W2554332656C2780182762 @default.
• W2554332656 hasConceptScore W2554332656C2780653079 @default.
• W2554332656 hasConceptScore W2554332656C2781290027 @default.
• W2554332656 hasConceptScore W2554332656C71924100 @default.
• W2554332656 hasLocation W25543326561 @default.
• W2554332656 hasOpenAccess W2554332656 @default.
• W2554332656 hasPrimaryLocation W25543326561 @default.
• W2554332656 isParatext "false" @default.
• W2554332656 isRetracted "false" @default.
• W2554332656 magId "2554332656" @default.
• W2554332656 workType "article" @default.